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In this paper, we will be discussing Abstracts #9061, #9062, #9065, #9072 and #9097 presented at the recent 2012 American Society 
of Clinical Oncology (ASCO) Annual Meeting. All of these abstracts explore innovative ways to control symptoms in cancer 
patients. We are hopeful that these methods are able to be used in symptomatic pancreatic cancer patients.  
 
What we Knew Before the 2012 American Society 
of Clinical Oncology (ASCO) Annual Meeting 
 
Pancreatic cancer is one of the most aggressive 
malignancies, as it is the fourth and sixth leading cause 
of cancer death in the United States and Europe, 
respectively. Despite many advances in diagnosis, 
therapy and palliation of pancreatic cancer, the overall 
survival of affected patients is still dismal [1]. Clinical 
manifestations of pancreatic cancer include pain, 
weight loss, anorexia cachexia syndrome, fatigue, 
nausea, vomiting, steatorrhea, dyspepsia, pruritus, 
jaundice, depression and deep venous thrombosis [2]. 
Toxicities and adverse events of chemotherapy should 
also be taken into account. Thus, affected patients 
require early and frequent palliative and supportive 
care, in order to achieve the improvement in quality of 
their life, regardless of their treatment status. 
Management of pancreatic cancer related symptoms 
has been a challenge for the oncological community. 
Efforts are underway in identifying palliative measures 
in this patient population that could also be cost 
effective [3]. 
In this article, we will attempt to describe findings 
from key abstracts presented at the recent ASCO 2012 
Annual Meeting relating to supportive care in patients 
with cancer. 
 
What We Learned at the 2012 American Society of 
Clinical Oncology (ASCO) Annual Meeting 
 
Cancer Related Fatigue and Cachexia 
 
Escalante et al. (Abstract #9072) studied the effects of 
extended release OROS® methylphenidate (Janssen 
Pharmaceuticals, Titusville, New Jersey, USA) on 
common cancer symptoms in 33 breast cancer patients 
[4]. The primary end point of the study was cancer 
related fatigue and secondary endpoints included 
cognitive function, ability to work at a job and patient 
perceptions. The study population was randomly 
divided into two groups, one receiving OROS® 
methylphenidate and the other receiving placebo. 
Table 1 shows the characteristics of patient population 
in this study. After two weeks on treatment, the groups 
were allowed to crossover. The primary endpoint was 
evaluated at baseline, two weeks and 4 weeks using 
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Table 1. Characteristics of the patient population of a study on the 
effects of extended release OROS® methylphenidate on common 
cancer symptoms in 33 breast cancer patients (Escalante et al., 
Abstract #9072) [4]. 
Mean age (range); years 58 (32-79) 
Patients with metastasis 30% 
Patients receiving chemotherapy 82% 
Patients receiving hormonal therapy 9% 
Patients receiving hormonal plus chemotherapy 9% 
Patients with ECOG status less than 1 94% 
Patients employed 54% 
Patients requiring pain medications 45% 
Mean baseline score for cancer related fatigue (range) 5.7 (4.1-8.6)
ECOG: Eastern Cooperative Oncology Group 
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Brief Fatigue Inventory (M.D. Anderson Cancer 
Center, Houston, TX, USA). Cancer related fatigue and 
other symptoms did not show statistically significant 
improvement between the two groups (P=0.54). Other 
secondary measures, such as work attendance and 
cognitive function, did show statistically significant 
improvement in patients who took methylphenidate. 
Patients reported high rates of subjective improvement 
while on methylphenidate and a high percentage also 
wanted to continue given the excellent tolerability of 
the drug. The authors also recorded the serum cytokine 
levels, but not conclusive data could be drawn. 
It appears that while fatigue was not well controlled, 
patients on methylphenidate had an improved overall 
quality of life with minimal side effects from the drug. 
We believe this is a worthwhile strategy to use in 
pancreatic cancer patients who would like to optimize 
the quality of their lives. 
The potential use of vitamin D and its analog in the 
prevention and treatment of cancer symptoms is an 
area under investigation. The effect of vitamin D 
supplementation on cancer-related fatigue in patients 
who had not received prior chemotherapy was studied 
by Trivanovic et al. (Abstract #9097) [5]. Sixty-nine 
patients with vitamin D deficiency participated in this 
prospective 3-month study. Patients were randomly 
divided into those receiving vitamin D3 daily for 3 
months during their treatment and those continuing 
their standard treatment without vitamin D3 
supplementation. Patients were eligible if the life 
expectancy was equal to, or greater than, 6 months, 
Eastern Cooperative Oncology Group (ECOG) 
performance status was between 0 and 3, the serum 25-
hydroxyvitamin D3 was low (cutoff value 32 ng/mL) 
and serum calcium level was normal. The measurement 
of cancer-related fatigue was based on the Functional 
Assessment of Cancer Therapy Fatigue module 
(FACT-F: www.facit.org). The primary measured 
endpoint was the changes in the FACT-F scale. The 
secondary endpoints were the improvement of vitamin 
D serum levels and safety. In this study, vitamin D3 
supplementation showed statistically significant 
improvement in fatigue (P<0.05) and corresponding 
increase in serum vitamin D levels (P<0.001) between 
the experimental and control groups. Both groups had 
similar grade 3 and 4 adverse events. Vitamin D 
appears to be a useful adjunctive therapy according to 
this small prospective study. This study certainly 
warrants a larger prospective randomized trial. In the 
meantime, vitamin D is cheap and easily available and 
given the acceptable safety profile can be offered to 
cancer patients with low vitamin D levels. 
Melatonin has been utilized to treat cancer related 
symptoms including fatigue, weight loss and 
depression. It has also been used with mixed results in 
the treatment of cachexia. This trial by Del Fabbro et 
al. reported in Abstract #9062 attempted to evaluate the 
utility of melatonin in controlling cancer related 
cachexia by designing a randomized controlled trial 
[6]. Patients with advanced lung or gastrointestinal 
cancer; appetite scores greater than 3 on a scale of 0 to 
10 (with 10 being the worst); weight loss equal to, or 
greater than, 5% within 6 months were eligible to 
participate in the trial. Symptoms were assessed using 
the Edmonton symptom assessment scale and quality 
of life was measured using functional assessment of 
anorexia/cachexia therapy. The trial was stopped early 
when an interim analysis done on 48 patients showed 
no difference in symptom control or quality of life. The 
authors concluded that melatonin does not have an 
effect on controlling cancer related symptoms in 
patients with advanced disease. 
 
Nausea and Vomiting 
 
Despite use of excellent drugs to control chemotherapy 
induced vomiting, our current arsenal is limited in 
controlling patient reported nausea. Although nausea 
and vomiting are often reported together, these are two 
different clinical entities that require different 
treatment modalities. While emesis is an objective 
finding, nausea is entirely subjective and therefore 
highly variable. Often, agents that are able to control 
emesis are only moderately successful at controlling 
nausea. We report findings of a small randomized trial 
reported in Abstract #9061 from Grunberg et al. 
designed to evaluate the use of dronabinol, a 
cannabinoid agent in controlling nausea [7]. Adults 
with solid tumors receiving doxorubicin at a dose equal 
to, or greater than, 40 mg/m2 or cyclophosphamide at a 
dose equal to, or greater than, 1,500 mg/m2 or who had 
also received mildly emetogenic chemotherapy on a 
prior occasion were eligible to participate in the trial. 
Patients were not eligible if: they were receiving other 
moderately or highly emetogenic chemotherapy; 
undergoing cranial, abdominal or pelvic radiation; had 
experienced chemotherapy induced vomiting or 
chemotherapy induced nausea with prior 
chemotherapy; had other causes of nausea and 
vomiting; had been receiving other antiemetics; or 
were habitual cannabinoid users. Sixty-two patients 
were eligible and all received 10 mg of i.v. 
dexamethasone and 0.25 mg of palonosteron. Patients 
were than randomized to the treatment arm and placebo 
arm. The treatment arm received dronabinol 5 mg by 
mouth three times a day for 5 days. Relevant data 
documenting nausea, vomiting and drug toxicity was 
collected during the 5 days. Table 2 shows the patient 
demographics. 
Table 2. Patient demographics of a small randomized trial designed 
to evaluate the use of dronabinol in controlling nausea (Grunberg et 

















Age: mean (range) 58 years (29-76) 
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No differences were noted with respect to 
chemotherapy induced vomiting. However differences 
were noted with respect to nausea. Table 3 summarizes 
the results. 
The authors concluded that dronabinol has a role in 
controlling chemotherapy induced nausea and could be 
used with drugs like dexamethasone and serotonin 
receptor antagonists like ondansetron. 
 
Role of Palliative Care in Comprehensive Cancer Care 
 
Supportive treatment should not only be offered to 
cancer patients in the late stages of the disease. It 
should be part of multidisciplinary approach at the 
initiation of the treatment. Kwon et al. (Abstract 
#9065) evaluated the clinical characteristics, symptoms 
and service utilization between patients with expected 
survival equal to, or greater than, 2 years or receiving 
curative treatment (early referrals) versus other cancer 
patients (late referrals) referred to a supportive care 
clinic [8]. The patient cohorts were selected from a 
single supportive care clinic. The patients also had to 
have a follow-up visit within 30 days between August 
2008 and October 2010. Of the 1,208 patients 
reviewed, 695 patients were documented to have a 
return visit within 30 days of the previous visit. Of the 
695 patients, 100 (14.4%) were able to be categorized 
as early referrals and another 100 patients were 
randomly selected from the pool of 695 patients and 
classified as late referrals. Baseline symptoms were 
similar between the two groups with the exception of 
insomnia which was noted to be statistically significant 
in the late referrals group. 
Table 4 summarizes the results. Early referral in this 
patient population resulted in decreased number of 
clinic visits per month with improvement in symptom 
burden. Furthermore, patients who were late referrals 





Supportive care in oncology is a highly evolving field. 
These abstracts presented at 2012 ASCO Annual 
Meeting support the use of unique modalities in 
controlling symptoms and also highlight the 
importance of ongoing research. Patients with 
advanced pancreatic cancer usually present with a high 
symptom burden and it is imperative that a 
multidisciplinary approach involving palliative care 
should be taken at the onset of care. The findings 
presented in these abstracts offer new and exciting 
approaches to symptom management in our patients 
including management of nausea and cancer related 
fatigue. Open communication regarding symptom 
management should be part of every clinic visit for 
these patients. Given the short duration of survival in 
patients with advanced pancreatic cancer, quality of 
life needs to be optimized. We believe further research 
is necessary in order to provide better care for cancer 
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Table 3. Results of a small randomized trial designed to evaluate the 
use of dronabinol in controlling nausea (Grunberg et al., Abstract 
#9061) [7]. 
 Dronabinol Placebo P value 
Duration of nausea 1.86 days 3.10 days 0.027 
No nausea 37% 17% 0.143 
Table 4. Results of a trial evaluating the clinical characteristics, 
symptoms and service utilization between patients with expected 
survival equal to, or greater than, 2 years or receiving curative 
treatment (early referrals) versus other cancer patients (late referrals) 
referred to a supportive care clinic (Kwon et al., Abstract #9065) [8].
Referrals Characteristics measured 
Early Late 
P value
Median age (years) 54 60 0.009 
Head and neck cancer 67% 6% <0.001
1st visit since the initial diagnosis (months) 3.8 16.2 <0.001
CAGE positive a 15% 4% 0.014 
Referred from radiation therapy clinic 49% 3% <0.001
Referred for treatment-related side effects 70% 48% 0.0002
Insomnia score 1.8 2 0.004 
Improvement in symptom distress score -5.5 -3 0.007 
Overall median number of visits 24 2.1 0.007 
Median visits per month 2.1 4.3 <0.001
a Authors do not specify in the abstract if they checked the gene or 
the protein product the patients. 
